Cohance Lifesciences Limited announced on June 30, 2026, that Jusmiral Holdings Limited, its promoter, has filed a disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The announcement was made at 15:58:01 on the stock exchanges.
The disclosure, dated April 7, 2026, confirms that Jusmiral Holdings Limited, along with persons acting in concert, has not created any new encumbrance on the shares of Cohance Lifesciences Limited. This declaration covers encumbrances other than those already disclosed during the financial year 2025-26, ensuring compliance with the takeover regulations.
Persons acting in concert with Jusmiral Holdings Limited include Berhyanda Limited, a fellow promoter entity, and Jusmiral Midco Limited. The filing was submitted to both BSE Limited and the National Stock Exchange of India Limited, with the company listed under scrip code 543064 and symbol COHANCE.
Cohance Lifesciences Limited, which was formerly known as Suven Pharmaceuticals Limited, operates in the pharmaceutical sector. The company's promoter group has disclosed this information as part of the mandatory requirements under the SEBI Takeover Regulations.
The disclosure was signed by Christodoulos Patsalides, a director of Jusmiral Holdings Limited, and was provided for the records of the stock exchanges. This submission provides material information regarding the encumbrance status of the company's shares.
Regulation 31(4) requires promoters and persons acting in concert to disclose any encumbrance on shares to the stock exchanges within specified timelines. This announcement by Cohance Lifesciences Limited fulfills that regulatory obligation for the financial year 2025-26.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.